Fogpharma Announces $178 Million Series D Financing To Advance Pipeline Of First-In-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Amount Raised
$178 Million
Round Type
Series D
CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, and PagsGroup, also participated.
Quick answer
Parabilis Medicines raised $178 Million in a Series D round, dated November 21, 2022. Investors: Casdin Capital, HBM Healthcare Investments, Farallon Capital Management, Gv, Cormorant Asset Management, Deerfield Management, Ven Bio Partners, Fidelity Management & Research Company and Milky Way Investments. Parabilis Medicines is based in Cambridge, Massachusetts, United States.
- How much did Parabilis Medicines raise?
- Parabilis Medicines raised $178 Million in a Series D round on November 21, 2022.
- Who invested in Parabilis Medicines?
- Casdin Capital, HBM Healthcare Investments, Farallon Capital Management, Gv, Cormorant Asset Management, Deerfield Management, Ven Bio Partners, Fidelity Management & Research Company and Milky Way Investments are named as investors in this round.
- What does Parabilis Medicines do?
- Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer.
- Where is Parabilis Medicines based and how big is it?
- Parabilis Medicines is based in Cambridge, Massachusetts, United States. Fundz records about 170 employees.
- Who are the decision-makers at Parabilis Medicines?
- Fundz holds 1 contact at Parabilis Medicines, including the Chairman, CEO and President. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Parabilis Medicines that raised within 45 days of this round, from Fundz verified event records.
- Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
- Os Therapies raised $2M on November 16, 2022.
- MBX Biosciences, Inc. raised $47M on November 7, 2022.
- HighTide Therapeutics raised $107M (Series C) on January 5, 2023.
- Citius Pharmaceuticals, Inc. raised $3.6M (Seed) on November 21, 2022.
- Renibus Therapeutics raised $33M (Funding Round) on November 14, 2022.
Who to call at Parabilis Medicines, and when
A new round usually means Parabilis Medicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Parabilis Medicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Parabilis Medicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Parabilis Medicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Parabilis Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Parabilis Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.